基于适配体识别-释放策略的表面增强拉曼散射（SERS）分析平台，用于高效敏感检测结直肠癌前病变

SERS Analysis Platform Based on Aptamer Recognition-Release Strategy for Efficient and Sensitive Diagnosis of Colorectal Precancerous Lesions

DOI 原文链接

用sci-hub下载

International Journal of Nanomedicine

影响因子:6.5

分区:医学2区 / 药学2区纳米科技3区

发表日期:2024

作者: Fengsong Chen, Yanhua Huang, Yongxia Liu, Yanwen Zhuang, Xiaowei Cao, Xiaogang Qin

DOI: 10.2147/IJN.S483261

摘要

结直肠癌（CRC）已成为全球公共卫生的重要挑战，因其发病率和死亡率高，亟需引起重视。定期筛查CRC对于早期发现癌前病变和癌症至关重要。本研究开发了一种新型的表面增强拉曼散射（SERS）分析平台，采用高通量微阵列芯片作为载体，Au/SnO2纳米环阵列（Au/SnO2 NRAs）作为基底。该平台利用适配体的识别-释放策略，实现对蛋白肿瘤标志物的高效敏感检测。在检测过程中，适配体与目标蛋白的高亲和性和高特异性导致原先结合在基底表面的SERS纳米探针被竞争性置换，从而携带拉曼报告基因的SERS纳米探针被释放，导致SERS信号强度降低。实验显示，该平台具有优异的检测性能，检测时间仅需15分钟，检测限（LOD）分别低至6.2×10^-12 g/mL（hnRNP A1）和6.51×10^-12 g/mL（S100P）。临床样本分析结果与酶联免疫吸附试验（ELISA）高度一致。该平台为结直肠癌前病变的早期诊断、风险评估和治疗监测提供了有力支持，具有广阔的临床应用前景。

Abstract

Colorectal cancer (CRC) has become a significant global public health challenge, demanding immediate attention due to its high incidence and mortality rates. Regular CRC screening is essential for the early detection of precancerous lesions and CRC.: We developed a novel surface-enhanced Raman scattering (SERS) analysis platform that employs high-throughput microarray chips as carriers and Au/SnO2 nanoring arrays (Au/SnO2 NRAs) as substrates. This platform utilizes an aptamer recognition-release strategy to achieve efficient and sensitive detection of protein tumor markers. In the detection process, the strong affinity and high specificity between the aptamer and the target protein result in competitive replacement of the SERS nanoprobes originally bound to the substrate surface. As a result, the SERS nanoprobes carrying Raman reporter genes are dislodged, leading to a reduction in the SERS signal intensity.The platform demonstrated excellent detection performance, with rapid detection completed within 15 minutes and limits of detection (LOD) as low as 6.2×10-12 g/mL for hnRNP A1 and 6.51×10-12 g/mL for S100P. Clinical samples analyzed using the SERS platform showed high consistency with enzyme-linked immunosorbent assay (ELISA) results.This platform offers strong support for the early detection, risk assessment, and treatment monitoring of colorectal cancer precancerous lesions, with broad potential for clinical applications.